GSK’s CFO set to retire next year
Select language to see a machine translation of this article. The original language of the Article is English and the translation is provided for your convenience.

GSK’s CFO set to retire next year

Glaxosmithkline (GSK) is set to see yet more change at the top. The pharmaceutical giant is still evolving as CEO Emma Walmsley – who took the reigns just over a year ago, in April 2017 – looks to shuffle her senior team and poach new talent from elsewhere. The latest announcement, however, concerns a resignation: Simon Dingemans, GKS’s chief financial officer, will step down in 2019. The company has committed to an internal and external search to find a replacement.

GSK’s share price has appreciated by 12% year to date

graph 2205 gsk


SOURCE: Yahoo Finance

Dingemans, a former Goldman Sachs investment banker that’s been with GSK for the past seven years, is leaving voluntarily – hence GSK will not be required to make any severance payment. However, his decision to leave will give Walmsley yet more room to put her stamp on the company’s upper echelons. She’s already appointed a new head of pharmaceuticals (Luke Miels), a new head of drug research (Hal Barron), and named Karenann Terrell head of digital operations – an area Reuters describes as “within Dingemans’s orbit.”

Dingemans helped oversee two transformative deals while at GSK, both of which concerned another pharmaceutical titan, Novartis. In 2015, he was involved in a major swapping of assets, and in March of this year, he was instrumental in arranging GSK’s buyout of Novartis from the pair’s healthcare joint venture. In his announcement, Dignemans said he was leaving at a time when the company had formed “strong foundations” to deliver positive financial performance.

In a statement, Emma Walmsley said: “Since joining GSK, Simon has played a very significant role in shaping the company. I am particularly grateful for his support and partnership since I took on the role of CEO and his counsel to me as we defined our new strategy.”


Dominion holds Glaxosmithkline in its Global Trends Managed Fund.

If you would you like to receive the Newsfeeds daily, please click here to sign up now!

Help us make this Newsfeed better by rating this article. 1 star = Poor and 5 stars = Excellent
0.0/5 rating (0 votes)

The views expressed in this article are those of the author at the date of publication and not necessarily those of Dominion Fund Management Limited. The content of this article is not intended as investment advice and will not be updated after publication. Images, video, quotations from literature and any such material which may be subject to copyright is reproduced in whole or in part in this article on the basis of Fair use as applied to news reporting and journalistic comment on events.